Free Trial

Bicara Therapeutics (BCAX) Competitors

Bicara Therapeutics logo
$10.84 -0.73 (-6.31%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$10.90 +0.06 (+0.60%)
As of 06/13/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCAX vs. NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, and IMCR

Should you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.

Bicara Therapeutics vs. Its Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

NewAmsterdam Pharma received 15 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. Likewise, 91.18% of users gave NewAmsterdam Pharma an outperform vote while only 72.73% of users gave Bicara Therapeutics an outperform vote.

CompanyUnderperformOutperform
NewAmsterdam PharmaOutperform Votes
31
91.18%
Underperform Votes
3
8.82%
Bicara TherapeuticsOutperform Votes
16
72.73%
Underperform Votes
6
27.27%

In the previous week, NewAmsterdam Pharma had 22 more articles in the media than Bicara Therapeutics. MarketBeat recorded 32 mentions for NewAmsterdam Pharma and 10 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.74 beat NewAmsterdam Pharma's score of 0.58 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
10 Very Positive mention(s)
2 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Bicara Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Bicara Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$47.14M48.13-$176.94M-$1.88-10.75
Bicara TherapeuticsN/AN/AN/AN/AN/A

NewAmsterdam Pharma currently has a consensus target price of $43.00, suggesting a potential upside of 112.77%. Bicara Therapeutics has a consensus target price of $31.86, suggesting a potential upside of 193.90%. Given Bicara Therapeutics' higher possible upside, analysts plainly believe Bicara Therapeutics is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bicara Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

Company Net Margins Return on Equity Return on Assets
NewAmsterdam PharmaN/A N/A N/A
Bicara Therapeutics N/A N/A N/A

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 15.5% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Bicara Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCAX vs. The Competition

MetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$630.98M$6.88B$5.57B$8.50B
Dividend YieldN/A2.48%5.27%4.17%
P/E RatioN/A8.4626.7519.65
Price / SalesN/A261.91403.98152.07
Price / CashN/A65.8538.2534.64
Price / BookN/A6.526.964.59
Net IncomeN/A$143.26M$3.23B$248.23M
7 Day Performance-5.74%-0.21%-1.22%-1.07%
1 Month Performance-25.09%10.62%6.34%2.59%
1 Year PerformanceN/A3.63%33.05%13.50%

Bicara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCAX
Bicara Therapeutics
2.0544 of 5 stars
$10.84
-6.3%
$31.86
+193.9%
N/A$630.98MN/A0.0032Analyst Revision
NAMS
NewAmsterdam Pharma
2.9663 of 5 stars
$18.93
+4.5%
$43.00
+127.2%
+5.3%$2.13B$47.14M-10.074Analyst Forecast
Analyst Revision
Gap Up
BLTE
Belite Bio
2.6268 of 5 stars
$65.02
+0.2%
$96.67
+48.7%
+19.2%$2.07BN/A-58.5810Short Interest ↑
Analyst Revision
HRMY
Harmony Biosciences
4.7702 of 5 stars
$35.56
+3.1%
$53.00
+49.0%
+13.5%$2.04B$744.85M16.85200Positive News
Short Interest ↑
Analyst Revision
KNSA
Kiniksa Pharmaceuticals
3.2361 of 5 stars
$27.92
+2.0%
$38.80
+39.0%
+50.8%$2.04B$481.17M-199.41220Analyst Upgrade
Insider Trade
VCEL
Vericel
2.4662 of 5 stars
$40.46
-2.0%
$61.14
+51.1%
+0.9%$2.04B$238.54M674.45300Positive News
High Trading Volume
DNLI
Denali Therapeutics
4.3316 of 5 stars
$13.96
+5.4%
$33.71
+141.5%
-29.8%$2.03B$330.53M-5.06430Positive News
Analyst Revision
Gap Down
High Trading Volume
CGON
CG Oncology
2.4419 of 5 stars
$26.59
+3.8%
$58.22
+119.0%
-25.4%$2.03B$662K-17.6161Positive News
Analyst Revision
Gap Down
VERA
Vera Therapeutics
2.8927 of 5 stars
$31.74
+67.5%
$65.00
+104.8%
-36.9%$2.02BN/A-12.1640Short Interest ↑
Analyst Revision
High Trading Volume
GMTX
Gemini Therapeutics
N/A$46.68
-0.4%
N/A+37.2%$2.02BN/A-46.6830News Coverage
High Trading Volume
IMCR
Immunocore
3.0551 of 5 stars
$38.65
+5.6%
$58.89
+52.4%
-9.8%$1.94B$333.58M-40.68320Positive News
Analyst Upgrade
Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:BCAX) was last updated on 6/15/2025 by MarketBeat.com Staff
From Our Partners